Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Breast Cancer Health Center

Font Size

New Use for Breast Cancer Drug OK'd

FDA Clears Femara for Postmenopausal Women After Breast Cancer Surgery
WebMD Health News

Dec. 29, 2005 -- The FDA has approved a new use for the breast cancer drug Femara.

Femara may now be taken by postmenopausal women with early, hormone-sensitive breast cancer immediately after surgery.

Femara had previously been an option for postmenopausal women with hormone-sensitive breast cancer who had already taken another breast cancer drug, tamoxifen.

Novartis -- the maker of Femara -- says Femara has already been approved for the same use in the U.K. and expects additional approvals in other countries in 2006.

Key Study

According to an FDA announcement, Femara's effectiveness in treating early breast cancer is based on an analysis of disease-free survival in patients who were treated and followed for an average of two years.

"Follow-up analyses will determine long-term outcomes for both safety and efficacy," states the FDA.

A news release from Novartis adds more details. Novartis states that the approval was based on results of a large, international study published in The New England Journal of Medicine.

In that study, postmenopausal women with hormone-sensitive early breast cancer were less likely to get breast cancer again if they took Femara instead of another breast cancer drug, tamoxifen, which also helped prevent breast cancer's return.

Targeting Estrogen

Femara and tamoxifen both target the female sex hormone, estrogen, which fuels some (but not all) breast cancers. But the two drugs work differently.

Tamoxifen, an older drug, has long been a cornerstone of breast cancer treatment. It blocks estrogen from binding onto cells.

Femara belongs to a newer (and more costly) family of drugs called aromatase inhibitors. Aromatase inhibitors target estrogen production, curbing the hormone's supply.

Aromatase inhibitors can raise a woman's risk of developing osteoporosis (thinning bones). In the Femara-tamoxifen study published in The New England Journal of Medicine, women taking Femara were more likely to fracture a bone than those taking tamoxifen.

Today on WebMD

Breast Cancer Overview
From self-exams and biopsies to reconstruction, we’ve got you covered.
Dealing with breast cancer
Get answers to your questions.
woman having mammogram
Experts don’t agree on all fronts, but you can be your own advocate.
woman undergoing breast cancer test
Many women worry. But the truth? Most abnormalities aren’t breast cancer.
Breast Cancer Treatments Improving
Resolved To Quit Smoking
Woman getting mammogram
Screening Tests for Women
ovarian cancer overview slideshow
serious woman
what is your cancer risk
10 Ways to Revitalize Slideshow